# Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy

> **NCT06271551** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Central Finland Hospital District** · enrollment: 310 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Transdermal estrogen
- **DRUG:** Active Comparator: Androgen deprivation therapy
- **BEHAVIORAL:** Resistance training

## Key facts

- **NCT ID:** NCT06271551
- **Lead sponsor:** Central Finland Hospital District
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06271551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06271551, "Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06271551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*